Nebula Research & Development LLC Invests $1.62 Million in United Therapeutics Co. (NASDAQ:UTHR)

Nebula Research & Development LLC acquired a new position in shares of United Therapeutics Co. (NASDAQ:UTHR) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,584 shares of the biotechnology company’s stock, valued at approximately $1,617,000.

Several other large investors also recently modified their holdings of the company. Parallel Advisors LLC lifted its position in shares of United Therapeutics by 2.8% during the fourth quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company’s stock valued at $385,000 after purchasing an additional 30 shares in the last quarter. Signaturefd LLC lifted its position in shares of United Therapeutics by 4.7% during the 4th quarter. Signaturefd LLC now owns 663 shares of the biotechnology company’s stock worth $234,000 after buying an additional 30 shares in the last quarter. Anchor Investment Management LLC lifted its position in shares of United Therapeutics by 12.0% during the 4th quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company’s stock worth $99,000 after buying an additional 30 shares in the last quarter. Great Lakes Advisors LLC boosted its stake in shares of United Therapeutics by 1.6% in the 4th quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company’s stock worth $697,000 after buying an additional 31 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund grew its holdings in shares of United Therapeutics by 0.4% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company’s stock valued at $3,214,000 after acquiring an additional 33 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Tommy G. Thompson sold 2,500 shares of United Therapeutics stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the completion of the sale, the director now owns 8,480 shares in the company, valued at approximately $2,703,424. This trade represents a 22.77 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $353.64, for a total value of $3,536,400.00. Following the transaction, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at $911,330.28. The trade was a 79.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 84,500 shares of company stock worth $28,179,150 over the last ninety days. Company insiders own 11.90% of the company’s stock.

Analysts Set New Price Targets

UTHR has been the topic of several research analyst reports. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, April 17th. UBS Group increased their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. Bank of America upgraded shares of United Therapeutics from an “underperform” rating to a “neutral” rating and set a $314.00 price objective for the company in a report on Monday, April 21st. Wells Fargo & Company reiterated an “equal weight” rating and issued a $314.00 target price (down from $395.00) on shares of United Therapeutics in a research note on Friday. Finally, HC Wainwright restated a “buy” rating and set a $425.00 price target on shares of United Therapeutics in a research note on Thursday, February 27th. Four investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $390.17.

United Therapeutics Trading Down 1.7 %

United Therapeutics stock opened at $291.38 on Friday. The firm has a market capitalization of $13.09 billion, a price-to-earnings ratio of 12.80, a P/E/G ratio of 0.97 and a beta of 0.63. The firm has a 50 day simple moving average of $308.67 and a 200 day simple moving average of $346.55. United Therapeutics Co. has a 1-year low of $233.31 and a 1-year high of $417.82.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. During the same period in the previous year, the company posted $4.36 EPS. On average, equities research analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.